# The HPV Vaccine Works—Unless Trust Collapses

England records no cervical cancer deaths among vaccinated young women in recent years, a milestone directly tied to the human papillomavirus vaccine introduced in 2006. The achievement demonstrates the vaccine's effectiveness at preventing the disease that killed thousands annually before immunization programs began.

Japan offers a cautionary case study. After the government suspended HPV vaccine recommendations in 2013 following safety concerns later found to be unfounded, vaccination rates plummeted from over 70 percent to below 1 percent. The country now faces a resurgence of cervical cancer cases among women who missed vaccination windows during those years of public hesitation.

Scientists attribute England's success to sustained confidence in the vaccine. The UK maintained its immunization program despite similar safety scares that circulated globally. Clinical data consistently shows the HPV vaccine prevents infection with high-risk strains responsible for roughly 70 percent of cervical cancers. The vaccine also protects against other cancers linked to HPV, including anal, oropharyngeal, and penile cancers.

The contrast between England and Japan underscores a critical vulnerability in public health: vaccine effectiveness depends not just on biological efficacy but on population-level trust. When that trust fractures, decades of progress become fragile. Japan's experience illustrates how misinformation can reverse gains in cancer prevention, particularly when official health authorities hesitate to correct false claims quickly.

Restoring Japan's HPV vaccination rates now requires rebuilding confidence that took years to damage. Public health officials across nations now recognize that scientific evidence alone cannot sustain vaccination programs. Communication strategy, rapid response to misinformation, and transparent dialogue with communities matter equally.

The England data reinforces what epidemiologists have long understood: vaccines prevent disease only when people receive them. The HPV vaccine's track record is clear. The